A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy

被引：0
|
作者：
Uchida, Yoshiyasu [1 ]
Ninomiya, Takashi [1 ]
Harada, Daijiro [1 ]
Kozuki, Toshiyuki [1 ]
机构：
[1] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO11-4
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [41] Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study
    Sun, R. -L.
    Liao, Y. -T.
    Shen, C. -I.
    Chiang, C. -L.
    Tseng, Y. -H.
    Hsiao, T. -H.
    Chao, H. -S.
    Luo, Y. -H.
    Chen, Y. -M.
    Huang, H. -C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S645 - S645
  • [42] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply
    Cho, Byoung C.
    Sethi, Seema
    Spira, Alexander I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 620 - 621
  • [43] PATTERN OF FAILURE AFTER COMBINED CHEMORADIOTHERAPY IN LOCALLY ADVANCED NSCLC: RETROSPECTIVE STUDY OF 62 CONSECUTIVE PATIENTS
    Khalil, A.
    Knap, M.
    Meldgaard, P.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S349 - S349
  • [44] Quality of Life in Long-Term Survivors with advanced EGFR-Mutated NSCLC
    Gijtenbeek, Rolof G. P.
    Bijlsma, Maria
    Damhuis, Ronald A. M.
    Van Der Wekken, Anthonie J.
    Stegmann, Mariken E.
    Buiter, Anne-Marije
    Reitsma, Bennie H.
    Staal-Van Brekel, Jeske A.
    Groen, Harry J. M.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [45] A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
    Huang, S.
    Li, L.
    Yan, N.
    Zhang, H.
    Guo, S.
    Guo, Q.
    Geng, D.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S433 - S433
  • [46] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [47] Durvalumab after Radiochemotherapy for locally advanced unresectable NSCLC - a Breakthrough
    Guckenberger, Matthias
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (01) : 95 - 97
  • [48] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
    Gulikers, Judith L.
    Veerman, G. D. Marijn
    Jebbink, Merel
    Kruithof, Paul D.
    Steendam, Christi M. J.
    Boosman, Rene J.
    Mathijssen, Ron H. J.
    Tjan-Heijnen, Vivianne C. G.
    Driessen, Johanna H. M.
    Dursun, Safiye
    Smit, Egbert F.
    Dingemans, Anne -Marie C.
    van Geel, Robin M. J. M.
    Croes, Sander
    Hendriks, Lizza E. L.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
  • [49] Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC
    Prabhash, Kumar
    Bharde, Atul
    Behel, Vichitra
    Ratnaparkhi, Mrunal
    Noronha, Vanita
    Patil, Vijay Maruti
    Choughule, Anuradha
    Chandrani, Pratik
    Dutt, Amit
    Jadhav, Bhagwat
    Prajapati, Sangeeta
    Haldar, Sumit
    Mobeen, Fauzul
    Menon, Nandini Sharrel
    Hariramani, Kanchan
    Basavalingegowda, Madhura
    Chaturvedi, Pankaj
    Khandare, Jayant
    Shafi, Gowhar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial
    Smeenk, M. M.
    van Diessen, J. N. A.
    Boellaard, T. N.
    Hartemink, K. J.
    de Vries, J. F.
    Badrising, S. K.
    Wondergem, M.
    Wittenberg, R.
    Monkhorst, K.
    van den Heuvel, M. M.
    Theelen, W. S. M. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S157 - S157
12345